Skip to main content
. 2022 Feb 7;10(2):e003465. doi: 10.1136/jitc-2021-003465

Figure 6.

Figure 6

Integrin αvβ6 blockade overcomes resistance to checkpoint blockade therapy in tumors without artificial ITGB6 overexpression. (A) RT-qPCR analysis of Itgb6 expression in murine carcinoma cell lines. (B) RT-qPCR analysis of Itgb6 expression in tumors grown from 4T1, CT26-ITGB6 and MC38-ITGB6 cells. (C) Experimental design of αITGB6 (6.8G6) and αPD-1 antibody administration. (D) Tumor volume development of subcutaneous 4T1 tumors treated with αITGB6, αPD-1, αITGB6 and αPD-1 or IgG control. (E) Tumor weight of subcutaneous 4T1 tumors treated with αITGB6, αPD-1, αITGB6 and αPD-1 or IgG control. Means and SDs are shown (n=5 mice, 2 tumors per mouse). One-way analysis of variance (ANOVA) (E) and two way ANOVA (D) with Tukey’s post-hoc test were used to calculate statistical significance. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.